European Commission Targets Teva Over Alleged Copaxone Antitrust Breach
Teva Prepared To Use All Legal And Procedural Rights Available
A European Commission investigation into Teva’s conduct over its Copaxone multiple sclerosis drug has led to the firm receiving a statement of objections, which details a preliminary finding that the company violated EU antitrust laws.
